NO320952B1 - Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl - Google Patents

Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl Download PDF

Info

Publication number: NO320952B1
Authority: NO; Norway
Prior art keywords: virus; solution; macromolecule; protein; filtration
Prior art date: 1994-06-23

Application number

NO19965523A

Other languages

English (en)

Norwegian (no)

Other versions

NO965523L (no

NO965523D0 (no

Inventor

Stefan Winge

Original Assignee

Octapharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-23

Filing date

1996-12-20

Publication date

2006-02-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662085&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320952(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-06-23 Priority claimed from SE9402254A external-priority patent/SE502820C2/sv

1996-12-20 Application filed by Octapharma Ag filed Critical Octapharma Ag

1996-12-20 Publication of NO965523L publication Critical patent/NO965523L/no

1996-12-20 Publication of NO965523D0 publication Critical patent/NO965523D0/no

2006-02-20 Publication of NO320952B1 publication Critical patent/NO320952B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 68
229920002521 macromolecule Polymers 0.000 title claims abstract description 46
238000011100 viral filtration Methods 0.000 title claims description 31
230000008569 process Effects 0.000 title claims description 17
235000002639 sodium chloride Nutrition 0.000 claims abstract description 76
150000003839 salts Chemical class 0.000 claims abstract description 55
238000001914 filtration Methods 0.000 claims abstract description 51
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 42
239000011780 sodium chloride Substances 0.000 claims abstract description 21
239000001509 sodium citrate Substances 0.000 claims abstract description 10
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 10
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 6
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 5
239000001632 sodium acetate Substances 0.000 claims abstract description 5
235000017281 sodium acetate Nutrition 0.000 claims abstract description 5
239000001103 potassium chloride Substances 0.000 claims abstract description 3
235000011164 potassium chloride Nutrition 0.000 claims abstract description 3
241000700605 Viruses Species 0.000 claims description 79
102000004169 proteins and genes Human genes 0.000 claims description 66
108090000623 proteins and genes Proteins 0.000 claims description 66
108010076282 Factor IX Proteins 0.000 claims description 21
102100022641 Coagulation factor IX Human genes 0.000 claims description 20
229960004222 factor ix Drugs 0.000 claims description 20
108010074605 gamma-Globulins Proteins 0.000 claims description 11
102000009027 Albumins Human genes 0.000 claims description 7
108010088751 Albumins Proteins 0.000 claims description 7
150000004676 glycans Chemical class 0.000 claims description 7
229920001282 polysaccharide Polymers 0.000 claims description 7
239000005017 polysaccharide Substances 0.000 claims description 7
108010054218 Factor VIII Proteins 0.000 claims description 6
102000001690 Factor VIII Human genes 0.000 claims description 6
229960000301 factor viii Drugs 0.000 claims description 6
229920001184 polypeptide Polymers 0.000 claims description 6
102000004196 processed proteins & peptides Human genes 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
102000004411 Antithrombin III Human genes 0.000 claims description 4
108090000935 Antithrombin III Proteins 0.000 claims description 4
229960005348 antithrombin iii Drugs 0.000 claims description 2
238000012217 deletion Methods 0.000 claims description 2
230000037430 deletion Effects 0.000 claims description 2
235000011083 sodium citrates Nutrition 0.000 claims description 2
239000001488 sodium phosphate Substances 0.000 abstract description 4
229910000162 sodium phosphate Inorganic materials 0.000 abstract description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
239000011591 potassium Substances 0.000 abstract description 2
229910052700 potassium Inorganic materials 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 65
239000000243 solution Substances 0.000 description 60
238000002474 experimental method Methods 0.000 description 25
230000000694 effects Effects 0.000 description 22
238000007873 sieving Methods 0.000 description 20
239000012460 protein solution Substances 0.000 description 19
238000010790 dilution Methods 0.000 description 18
239000012895 dilution Substances 0.000 description 18
238000012545 processing Methods 0.000 description 14
238000011026 diafiltration Methods 0.000 description 13
239000000047 product Substances 0.000 description 13
239000000706 filtrate Substances 0.000 description 11
230000035699 permeability Effects 0.000 description 11
241000125945 Protoparvovirus Species 0.000 description 10
230000014759 maintenance of location Effects 0.000 description 10
102000008100 Human Serum Albumin Human genes 0.000 description 9
108091006905 Human Serum Albumin Proteins 0.000 description 9
239000013621 viresolve pro solution Substances 0.000 description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
230000008901 benefit Effects 0.000 description 7
239000012528 membrane Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 5
239000004019 antithrombin Substances 0.000 description 5
210000004779 membrane envelope Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000004471 Glycine Substances 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
239000011148 porous material Substances 0.000 description 4
239000012266 salt solution Substances 0.000 description 4
238000005185 salting out Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108010071619 Apolipoproteins Proteins 0.000 description 3
102000007592 Apolipoproteins Human genes 0.000 description 3
241000991587 Enterovirus C Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
239000012467 final product Substances 0.000 description 3
150000002337 glycosamines Chemical class 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000012620 biological material Substances 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000011017 operating method Methods 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
108010025139 recombinant factor VIII SQ Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010059886 Apolipoprotein A-I Proteins 0.000 description 1
102000005666 Apolipoprotein A-I Human genes 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
-1 antithrombin III Proteins 0.000 description 1
108010073614 apolipoprotein A-IV Proteins 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002628 heparin derivative Substances 0.000 description 1
239000002634 heparin fragment Substances 0.000 description 1
229960004336 human antithrombin iii Drugs 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000013386 optimize process Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000014616 translation Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
108010048348 zinc hemoglobin Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Water Supply & Treatment (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Glass Compositions (AREA)
Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

NO19965523A 1994-06-23 1996-12-20 Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl NO320952B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9402254A SE502820C2 (sv)	1994-06-23	1994-06-23	Filtrering
SE9500724A SE9500724D0 (sv)	1994-06-23	1995-02-24	Filtrering
PCT/SE1995/000777 WO1996000237A1 (en)	1994-06-23	1995-06-22	Filtration

Publications (3)

Publication Number	Publication Date
NO965523L NO965523L (no)	1996-12-20
NO965523D0 NO965523D0 (no)	1996-12-20
NO320952B1 true NO320952B1 (no)	2006-02-20

Family

ID=26662085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19965523A NO320952B1 (no)	1994-06-23	1996-12-20	Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl

Country Status (16)

Country	Link
US (4)	US6486306B1 (ja)
EP (1)	EP0796269B1 (ja)
JP (1)	JP3676370B2 (ja)
AT (1)	ATE212354T1 (ja)
CA (1)	CA2192683C (ja)
DE (2)	DE69525176T2 (ja)
DK (1)	DK0796269T3 (ja)
ES (1)	ES2105992T3 (ja)
FI (1)	FI965145A0 (ja)
GR (1)	GR970300038T1 (ja)
MX (1)	MX9606639A (ja)
NO (1)	NO320952B1 (ja)
NZ (1)	NZ288789A (ja)
PT (1)	PT796269E (ja)
SE (1)	SE9500724D0 (ja)
WO (1)	WO1996000237A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9500724D0 (sv) *	1994-06-23	1995-02-24	Pharmacia Ab	Filtrering
SE9500778D0 (sv) *	1995-03-03	1995-03-03	Pharmacia Ab	Process for producing a protein
SE9603068D0 (sv) *	1996-08-23	1996-08-23	Pharmacia & Upjohn Ab	Process for purifying a protein
SE9603303D0 (sv)	1996-09-11	1996-09-11	Pharmacia & Upjohn Ab	Process for purifying a protein
EP0860444A1 (en) *	1997-02-24	1998-08-26	Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB)	Method for removing viruses from a protein solution
US6045588A (en)	1997-04-29	2000-04-04	Whirlpool Corporation	Non-aqueous washing apparatus and method
US6096872A (en) *	1997-10-14	2000-08-01	Ortho Diagnostic Systems, Inc.	Viral clearance process
FR2772381B1 (fr) *	1997-12-15	2001-06-08	Lab Francais Du Fractionnement	Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6861001B2 (en) *	1999-12-02	2005-03-01	The General Hospital Corporation	Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
ATE555666T1 (de)	2002-05-23	2012-05-15	Ortho Clinical Diagnostics Inc	Einfang, konzentration und quantifizierung eines abnormalen prionproteins aus biologischen flüssigkeiten mittels tiefenfiltration
PT1534404E (pt)	2002-06-14	2007-03-30	Centocor Inc	Utilização de um modificador de clatratos para promover a passagem de proteínas durante a nanofiltração
JP2004099506A (ja) *	2002-09-09	2004-04-02	Mitsubishi Rayon Co Ltd	アミノ酸アミドの製造方法
ES2543978T3 (es) *	2003-04-09	2015-08-26	The Chemo-Sero-Therapeutic Research Institute	Proceso para la producción de una preparación de albúmina
CN100398642C (zh) *	2003-06-20	2008-07-02	迈克必斯生物***公司	病毒生产的改进
JP4558652B2 (ja) *	2003-06-20	2010-10-06	マイクロビクス・バイオシステムズ・インコーポレイテツド	ウイルス生産の改善
FR2861395B1 (fr)	2003-10-23	2006-02-17	Lab Francais Du Fractionnement	Facteur viii viralement securise a faible teneur en multimeres superieurs
US7739891B2 (en)	2003-10-31	2010-06-22	Whirlpool Corporation	Fabric laundering apparatus adapted for using a select rinse fluid
US7695524B2 (en)	2003-10-31	2010-04-13	Whirlpool Corporation	Non-aqueous washing machine and methods
ES2926359T3 (es)	2003-12-01	2022-10-25	Novo Nordisk Healthcare Ag	Filtración de virus de composiciones líquidas del Factor VII
CA2555412C (en)	2004-02-23	2013-06-25	Crucell Holland B.V.	Virus purification methods
FR2866890B1 (fr) *	2004-02-27	2008-04-04	Lab Francais Du Fractionnement	Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
US7837741B2 (en)	2004-04-29	2010-11-23	Whirlpool Corporation	Dry cleaning method
US7141171B2 (en) *	2004-05-21	2006-11-28	Wisconsin Alumni Research Foundation	Membrane cascade-based separation
AU2005229674B2 (en)	2004-11-18	2010-11-04	Kedrion Melville Inc.	Low concentration solvent/detergent process of immuneglobulin with pre-treatment
CA2602944C (en)	2005-04-11	2015-08-11	Crucell Holland B.V.	Virus purification using ultrafiltration
US7966684B2 (en)	2005-05-23	2011-06-28	Whirlpool Corporation	Methods and apparatus to accelerate the drying of aqueous working fluids
RU2468032C2 (ru) *	2006-06-26	2012-11-27	Омрикс Биофармасьютикалс Инк.	Способ очистки раствора тромбина от инфекционных частиц
JP5579599B2 (ja) *	2007-06-15	2014-08-27	アムジエン・インコーポレーテツド	バイオリアクターにおいて使用する細胞培養培地の処理方法
KR100870423B1 (ko) *	2007-06-27	2008-11-26	주식회사 하이닉스반도체	반도체메모리소자
US7989593B1 (en)	2010-05-27	2011-08-02	Bing Lou Wong	Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en)	2010-06-23	2011-04-26	Bing Lou Wong	Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en)	2010-06-23	2011-11-01	Billion King, Ltd.	Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en)	2011-04-29	2011-12-27	Bing Lou Wong	Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US9359397B2 (en)	2011-06-24	2016-06-07	Asahi Kasei Medical Co., Ltd.	Method for manufacturing protein drug
US20130052232A1 (en)	2011-08-31	2013-02-28	Bing Lou Wong	Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US9294158B2 (en)	2012-08-07	2016-03-22	Broadcom Corporation	Broadcast audio service
NZ631126A (en) *	2013-08-08	2018-06-29	Csl Ltd	Contaminant removal method
US10053296B2 (en)	2016-09-19	2018-08-21	Asgco Manufacturing, Inc.	Return idler trainer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870801A (en)	1968-08-09	1975-03-11	Lever Brothers Ltd	Fluid aqueous protein compositions and food products prepared therefrom
US3919044A (en)	1973-03-28	1975-11-11	Armour Pharma	Processes for concentrating and purifying viruses and viral antigens
US3874999A (en)	1973-10-31	1975-04-01	American Cyanamid Co	Process for the purification of virus vaccine
CA1099576A (en)	1978-03-23	1981-04-21	Chester D. Myers	Improved process for isolation of proteins
US4473494A (en)	1983-05-04	1984-09-25	The United States Of America As Represented By The Secretary Of The Army	Preparation of stroma-free, non-heme protein-free hemoglobin
US4684723A (en) *	1985-09-11	1987-08-04	Miles Laboratories, Inc.	Method of separating proteins from aqueous solutions
JPH0720986B2 (ja)	1985-10-07	1995-03-08	日本ケミカルリサ−チ株式会社	生理活性物質の製造法
AU605901B2 (en)	1987-09-11	1991-01-24	Ares Trading S.A.	Purification process
RU1781355C (ru) *	1990-04-23	1992-12-15	В.П.Широбоков, Л.Я.Палиенко, А.И.Евтушенко, Л.А Коптюх, Ю.В.Загороднюк и К.Д Стеценко	Фильтрующий материал
US5017292A (en)	1990-05-10	1991-05-21	Millipore Corporation	Membrane, process and system for isolating virus from solution
US5076933A (en)	1990-06-29	1991-12-31	Coulter Corporation	Process and apparatus for removal of dna and viruses
US5221483A (en) *	1990-06-29	1993-06-22	Coulter Corporation	Process and apparatus for removal of DNA, viruses and endotoxins
SE9301582D0 (sv)	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Purification of plasma proteins
SE9500724D0 (sv) *	1994-06-23	1995-02-24	Pharmacia Ab	Filtrering

1995
- 1995-02-24 SE SE9500724A patent/SE9500724D0/xx unknown
- 1995-06-22 WO PCT/SE1995/000777 patent/WO1996000237A1/en active IP Right Grant
- 1995-06-22 JP JP50306296A patent/JP3676370B2/ja not_active Expired - Fee Related
- 1995-06-22 PT PT95923651T patent/PT796269E/pt unknown
- 1995-06-22 US US08/750,664 patent/US6486306B1/en not_active Expired - Fee Related
- 1995-06-22 ES ES95923651T patent/ES2105992T3/es not_active Expired - Lifetime
- 1995-06-22 NZ NZ288789A patent/NZ288789A/en not_active IP Right Cessation
- 1995-06-22 MX MX9606639A patent/MX9606639A/es not_active IP Right Cessation
- 1995-06-22 DK DK95923651T patent/DK0796269T3/da active
- 1995-06-22 CA CA002192683A patent/CA2192683C/en not_active Expired - Fee Related
- 1995-06-22 AT AT95923651T patent/ATE212354T1/de not_active IP Right Cessation
- 1995-06-22 DE DE69525176T patent/DE69525176T2/de not_active Revoked
- 1995-06-22 DE DE0796269T patent/DE796269T1/de active Pending
- 1995-06-22 EP EP95923651A patent/EP0796269B1/en not_active Revoked
1996
- 1996-12-20 NO NO19965523A patent/NO320952B1/no not_active IP Right Cessation
- 1996-12-20 FI FI965145A patent/FI965145A0/fi not_active Application Discontinuation
1997
- 1997-11-28 GR GR970300038T patent/GR970300038T1/el unknown
2000
- 2000-02-23 US US09/511,953 patent/US6399357B1/en not_active Expired - Fee Related
2002
- 2002-11-26 US US10/304,902 patent/US20030191292A1/en not_active Abandoned
2005
- 2005-02-23 US US11/064,770 patent/US20050203285A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2105992T2 (es)	1997-11-01
DK0796269T3 (da)	2002-05-06
NZ288789A (en)	1997-12-19
ES2105992T3 (es)	2002-09-16
AU682274B2 (en)	1997-09-25
DE69525176D1 (de)	2002-03-14
ES2105992T1 (es)	1997-11-01
DE69525176T2 (de)	2002-06-27
MX9606639A (es)	1997-03-29
NO965523L (no)	1996-12-20
SE9500724D0 (sv)	1995-02-24
DE796269T1 (de)	1998-01-02
FI965145A (fi)	1996-12-20
US20030191292A1 (en)	2003-10-09
CA2192683A1 (en)	1996-01-04
GR970300038T1 (en)	1997-11-28
EP0796269B1 (en)	2002-01-23
US6399357B1 (en)	2002-06-04
WO1996000237A1 (en)	1996-01-04
JPH10502074A (ja)	1998-02-24
FI965145A0 (fi)	1996-12-20
US6486306B1 (en)	2002-11-26
PT796269E (pt)	2002-06-28
US20050203285A1 (en)	2005-09-15
CA2192683C (en)	2005-07-05
ATE212354T1 (de)	2002-02-15
NO965523D0 (no)	1996-12-20
EP0796269A1 (en)	1997-09-24
JP3676370B2 (ja)	2005-07-27
AU2813295A (en)	1996-01-19

Legal Events

Date	Code	Title	Description
2011-01-31	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO320952B1 (no)	2006-02-20	Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl
JP3094167B2 (ja)	2000-10-03	免疫血清グロブリンの精製方法
US4877866A (en)	1989-10-31	Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation
CA2254871C (en)	2008-03-25	Purification of biologically active peptides from milk
RU2000113224A (ru)	2002-05-20	Способ продуцирования в высокой степени вирусобезопасных компонентов для получения фибринового клея из пула плазмы человека
AU709584B2 (en)	1999-09-02	Industrial production process for a vaccine against Japanese encephalitis, and vaccine obtained
US4386068A (en)	1983-05-31	Antihemophilic factor concentrate and method for preparation
NO863424L (no)	1986-08-26	Fremgangsmaate for rensing av et interferon.
EP0176926B1 (en)	1989-06-28	Process for producing a high purity antihemophilic factor concentrate
NO323460B1 (no)	2007-05-14	Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus
US4199450A (en)	1980-04-22	Process of separating from an aqueous medium a protein or a morphologically organized unit by liquid exclusion chromatography
IL177286A (en)	2012-08-30	Albumin purification method comprising a nanofiltration step and solution and composition for therapeutic use containing same
JP4312381B2 (ja)	2009-08-12	濾過によるウイルス的に安全な因子ｖｉｉｉ溶液の調製方法
US8293242B2 (en)	2012-10-23	Ultra-high yield of alpha-1-anti-trypsin
CN110678481B (zh)	2023-10-31	用于纯化白蛋白的方法
RU2617960C2 (ru)	2017-04-28	Очистка ингибитора альфа1 протеиназы, полученного из культуры клеток
AU682274C (en)	1999-10-07	Filtration
US10800820B2 (en)	2020-10-13	Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
JPH08787B2 (ja)	1996-01-10	ガンマグロブリン含有組成物の製造法
RU2066188C1 (ru)	1996-09-10	Способ получения человеческого лейкоцитарного интерферона
EP0126789B1 (en)	1989-01-25	Antihemophilic factor concentrate and process for its preparation
JP2678193B2 (ja)	1997-11-17	ヒト血漿由来血液凝固第ｘ▲ｉｉｉ▼因子の製造方法
SE502820C2 (sv)	1996-01-22	Filtrering
JP2000212097A (ja)	2000-08-02	伝達性海綿状脳症病原因子を除去する方法
NO149610B (no)	1984-02-13	Fremgangsmaate for rensing av den antihemofile faktor, faktor viii